logo
Share SHARE
FONT-SIZE Plus   Neg

BASi Names CFO Jacqueline Lemke To Addl. Posts Of Interim President & CEO

Bioanalytical Systems, Inc., or BASi, (BASI) said CFO Jacqueline Lemke has been named to the additional posts of interim President & CEO. Lemke succeeds Anthony Chilton, who has resigned as CEO to pursue other opportunities.

"...As interim President and CEO, with continuing responsibility as CFO, we expect Jackie to complete the transformation of BASi and deliver the growth and profitability we believe this company is capable of delivering. Board member Richard Johnson and I, with more than 60 years of combined major pharma and CRO experience, will work closely with Jackie during this interim period," said John Landis, Chairman.

Lemke has more than 20 years of experience in critical financial reporting and management positions, most recently as Vice President of Finance and Global CFO of Remy, Inc.

BASi also announced the resignation of Alberto Hidalgo, Vice President, Business Development and Marketing.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Nokia Corp. were gaining around 6 percent in mid-morning trading in Finland after the network equipment maker reported Thursday narrower loss in its first quarter. The company also reiterated its fiscal 2017 outlook for total cost savings. CEO Rajeev Suri said, "Overall, given Nokia's performance in the first quarter, I am optimistic about the year ahead, even if cautiously so." Aerospace and defense major Airbus Group SE reported Thursday higher profit and revenues in its first quarter with growth in all segments, except defence. Adjusted EBIT, a key earnings metric, meanwhile declined from last year. Looking ahead, for fiscal 2017, Airbus continues to expect mid-single-digit percentage growth in adjusted earnings per share and adjusted EBIT. Shares of AstraZeneca Plc were declining in the morning trading in London after the British drug giant reported Thursday weak profit and revenues in its first quarter, as product sales were hurt mainly by the residual impact of the US Crestor patent expiry. Core profit, however, increased with improved cost control. Further, the company confirmed its financial guidance for 2017.
comments powered by Disqus
Follow RTT